Description

Tingrex (memantine) Coated Tablets 10 mg. №60

Ingredients

Active ingredient: Memantine hydrochloride. Inactive ingredients: microcrystalline cellulose, colloidal silicon dioxide, talc, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol.

Dosage

Recommended dosage: The usual starting dose is 5 mg once daily. The dose is then increased by 5 mg weekly. The maximum recommended dose is 20 mg per day.

Indications

Indicated for: Treatment of moderate to severe Alzheimer’s disease.

Contraindications

Do not use Tingrex if: allergic to memantine or any ingredients in the product, have severe kidney problems, or are pregnant or breastfeeding.

Directions

Administration: Swallow the tablet whole with water. Can be taken with or without food. Do not crush, chew, or break the tablet.

Scientific Evidence

Memantine, the active ingredient in Tingrex, works by regulating the activity of glutamate, a neurotransmitter involved in learning and memory. Studies have shown that memantine can help improve cognitive function and slow down the progression of Alzheimer’s disease. Research published in the Journal of Alzheimer’s Disease demonstrated the efficacy of memantine in improving cognitive function and daily living activities in patients with Alzheimer’s disease.

Additional Information

It is important to follow the prescribed dosage and not exceed the recommended amount. Tingrex may cause dizziness or drowsiness, so caution is advised when operating machinery or driving. Consult a healthcare professional before starting Tingrex, especially if you have any medical conditions or are taking other medications.

Pharmacological Effects

Memantine acts as an uncompetitive NMDA receptor antagonist, which helps regulate the activity of glutamate in the brain. By modulating glutamate levels, memantine protects brain cells from excessive stimulation, which is beneficial in Alzheimer’s disease. This mechanism of action differentiates memantine from other Alzheimer’s medications, providing a unique approach to managing the disease.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the effectiveness of memantine in improving cognitive function, behavior, and overall functioning in patients with Alzheimer’s disease. Compared to other Alzheimer’s medications, memantine has shown comparable efficacy with a favorable side effect profile. A study published in the Journal of Clinical Psychopharmacology compared the effectiveness of memantine with other Alzheimer’s drugs and found memantine to be well-tolerated and effective in managing symptoms.

References:
– Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003 Apr 3;348(14):1333-41.
– Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):317-24.